Article Text

PDF

Use of nitric oxide inhalation in COPD
  1. TIM W HIGENBOTTAM,
  2. MOHAMMED ASIF,
  3. KEITH MCCORMACK,
  4. TOM E SIDDONS,
  5. ERIC A G DEMONCHEAUX
  1. Respiratory Medicine
  2. Division of Clinical Sciences (CSUHT)
  3. University of Sheffield Medical School
  4. Sheffield S10 2RX
  5. UK
    1. KUMAR ASHUTOSH
    1. Chief, Pulmonary Medicine/Critical Care
    2. Department of Veterans Affairs Medical Center
    3. Syracuse
    4. New York, USA
    5. SUNY Upstate Medical University
    6. Syracuse
    7. New York, USA
      1. KISHORE PHADKE
      1. Chief, Pulmonary Medicine/Critical Care
      2. Department of Veterans Affairs Medical Center
      3. Syracuse
      4. New York, USA
      5. SUNY Upstate Medical University
      6. Syracuse
      7. New York, USA

        Statistics from Altmetric.com

        Ashutosh et al 1report that inhaled nitric oxide (iNO) lowers pulmonary vascular resistance (PVR) in stable patients with chronic obstructive pulmonary disease (COPD) receiving long term oxygen therapy (24 hours' treatment, randomised, double blind, crossover study). Oxygen was delivered via face mask at a rate of 2 l/min into which NO was diluted down from 200 ppm (cylinder) to achieve a final concentration of 25 ppm inspired. The authors conclude that vasodilation and relaxation of the pulmonary arterial bed is responsible for the fall in PVR.

        Pulmonary arterial pressures were measured by cardiac catheterisation. Expired air was collected for five minutes and carbon dioxide output (V˙co 2) and deadspace/tidal volume ratio (Vd/Vt) were measured. Cardiac output (CO) was determined by the Fick equation using V˙co 2 and calculations of arterial and mixed venous carbon dioxide contents from directly measured mixed venous and arterial oxygen and carbon dioxide (Po 2 and Pco 2) based on McHardy's equations. Although these measurements were validated against the thermodilution technique in 24 samples obtained from four patients, the correlation was very low (r= 0.6; p<0.01) and individual values agreed within one litre of each other. PVR values obtained by two methods were better with a correlation of r = 0.96, but this is dominated by the pulmonary artery pressure (PAP).

        Analysis of table 2 shows that, of all the haemodynamic parameters recorded, only CO was shown to increase after 24 hours of NO inhalation (by up to 80% in some patients). Pulmonary artery pressure (PAP) and pulmonary wedge pressure (P wedge) were unchanged. The fall in PVR can therefore be mostly attributed to the increase in CO and not to vasodilation of the pulmonary arterial bed. They also suggest that iNO may have improved CO by reducing the right ventricular afterload in these patients with severe COPD (forced expiratory volume in one second (FEV1) = 0.89 (0.4) 1 (25.8 (9.4)% predicted); forced vital capacity (FVC) = 2.1(0.75) 1).

        We and others have reported no effect on CO of short term iNO.2 3 Dosing iNO in patients with COPD is a challenging task. Matching inhaled gas flow rate to the frequency of breathing is limited with continuous NO delivery systems, but this problem is minimised by pulsing a small volume of NO at the beginning of the breath.4 Trials of long term exposure to iNO in ambulatory patients have started, and preliminary data suggest that chronic exposure to pulsed NO does not affect CO in hypoxaemic patients. The positive inotropic effect reported by Ashutosh et al (reduction in right ventricular afterload, thus increase in CO) is interesting and worthy of further investigation but, given the caveats of their methods to measure CO, must remain preliminary at the best. These results must be confirmed by others before we give too much credence to the authors' observations.

        References

        authors' reply We thank Dr Higenbottam and colleagues for their interest in our work and appreciate their thoughtful comments. We would like to address some of their concerns as follows.

        The non-invasive CO2 Fick method is considered to be a reliable technique both on theoretical and experimental grounds for measurement of cardiac output (CO).1-1-1-3 The correlation between the CO measured by the two techniques as noted by us was sufficiently significant to allow the use of the CO2 Fick method with reasonable confidence.1-4

        Our study was not designed to investigate the possible mechanisms for the observed changes in CO. We can only speculate that our patients had underlying cardiac dysfunction from an increased afterload due to pulmonary hypertension that responded to the administration of nitric oxide (NO), leading to the rise in CO. A fall in the pulmonary artery pressure (PAP) was prevented by a concomitant rise in CO. Although pulmonary vascular resistance (PVR) is a derived measurement, its fall in the face of a rising CO can only indicate a relaxation of the pulmonary arterial vasculature to accommodate the increased flow without a rise in pressure. We wish to point out that a similar rise in CO with little change in PAP has also been noted by other workers.1-5 1-6 In a recent study Robbins and colleague noted an increase in CO with a fall in PVR without a fall in PAP in two of three patients with the use of NO and in one of three patients with epoprostenol.1-7

        We fully agree with their final comment that our study results need to be evaluated and confirmed by larger and more rigorous studies.

        References

        1. 1-1.
        2. 1-2.
        3. 1-3.
        4. 1-4.
        5. 1-5.
        6. 1-6.
        7. 1-7.
        View Abstract

        Request permissions

        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.